JP2016527322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527322A5 JP2016527322A5 JP2016533501A JP2016533501A JP2016527322A5 JP 2016527322 A5 JP2016527322 A5 JP 2016527322A5 JP 2016533501 A JP2016533501 A JP 2016533501A JP 2016533501 A JP2016533501 A JP 2016533501A JP 2016527322 A5 JP2016527322 A5 JP 2016527322A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- quinolone
- tube
- item
- syringe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 8
- 229940072132 quinolone antibacterials Drugs 0.000 claims description 8
- 206010033078 Otitis media Diseases 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- FYMHQCNFKNMJAV-HOTGVXAUSA-N finafloxacin Chemical compound C12=C(C#N)C(N3C[C@@H]4OCCN[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 FYMHQCNFKNMJAV-HOTGVXAUSA-N 0.000 claims description 4
- 229960002839 finafloxacin Drugs 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000022760 infectious otitis media Diseases 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 229960001048 fluorometholone Drugs 0.000 claims description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 229960003923 gatifloxacin Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960001798 loteprednol Drugs 0.000 claims description 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 229960003702 moxifloxacin Drugs 0.000 claims description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 4
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- -1 rimisolone Chemical compound 0.000 claims 1
- 210000003454 tympanic membrane Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864713P | 2013-08-12 | 2013-08-12 | |
| US61/864,713 | 2013-08-12 | ||
| PCT/US2014/050777 WO2015023697A1 (en) | 2013-08-12 | 2014-08-12 | Method for treating otic infections after tympanostomy tube placement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016527322A JP2016527322A (ja) | 2016-09-08 |
| JP2016527322A5 true JP2016527322A5 (enExample) | 2017-09-07 |
Family
ID=51610417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533501A Pending JP2016527322A (ja) | 2013-08-12 | 2014-08-12 | 鼓膜チューブ配置後の耳感染症の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150045739A1 (enExample) |
| EP (1) | EP3033074A1 (enExample) |
| JP (1) | JP2016527322A (enExample) |
| KR (1) | KR20160040463A (enExample) |
| CN (1) | CN105358131A (enExample) |
| AU (1) | AU2014306781A1 (enExample) |
| BR (1) | BR112016000381A8 (enExample) |
| CA (1) | CA2916535A1 (enExample) |
| HK (1) | HK1221151A1 (enExample) |
| MX (1) | MX2016001912A (enExample) |
| RU (1) | RU2016101960A (enExample) |
| WO (1) | WO2015023697A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| WO2018053173A1 (en) | 2016-09-16 | 2018-03-22 | Otonomy, Inc. | Otic gel formulations for treating otitis externa |
| CA3150482A1 (en) | 2019-09-16 | 2021-03-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3906365A1 (de) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| US5167642A (en) * | 1990-08-27 | 1992-12-01 | Baxter International Inc. | Sheath for a blunt cannula |
| DE19652239A1 (de) | 1996-12-16 | 1998-06-18 | Bayer Ag | Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen |
| US6716830B2 (en) | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| US6599280B1 (en) * | 2000-10-20 | 2003-07-29 | Bausch & Lomb Incorporated | Surgical kit for the preparation of tamponade gas |
| US20050009931A1 (en) * | 2003-03-20 | 2005-01-13 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| AU2004258746A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| TR200403298A1 (tr) * | 2004-12-03 | 2006-02-21 | Kutluhan Ahmet | Mastoid antral ventilasyon tüpü |
| US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
| US8088095B2 (en) * | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
| EP2216042A1 (en) * | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
| US8536167B2 (en) * | 2009-07-02 | 2013-09-17 | Alcon Research, Ltd. | Methods for treating ophthalmic, otic, or nasal infections |
| WO2013054330A1 (en) * | 2011-10-10 | 2013-04-18 | Otic Pharma Ltd. | Foam formulations |
| WO2013106230A1 (en) * | 2012-01-10 | 2013-07-18 | Entrx LLC | Otic formulations, methods and devices |
-
2014
- 2014-08-12 MX MX2016001912A patent/MX2016001912A/es unknown
- 2014-08-12 JP JP2016533501A patent/JP2016527322A/ja active Pending
- 2014-08-12 EP EP14772237.5A patent/EP3033074A1/en not_active Withdrawn
- 2014-08-12 US US14/458,176 patent/US20150045739A1/en not_active Abandoned
- 2014-08-12 KR KR1020157035844A patent/KR20160040463A/ko not_active Withdrawn
- 2014-08-12 CN CN201480037275.0A patent/CN105358131A/zh active Pending
- 2014-08-12 HK HK16109251.7A patent/HK1221151A1/zh unknown
- 2014-08-12 WO PCT/US2014/050777 patent/WO2015023697A1/en not_active Ceased
- 2014-08-12 CA CA2916535A patent/CA2916535A1/en not_active Abandoned
- 2014-08-12 BR BR112016000381A patent/BR112016000381A8/pt not_active Application Discontinuation
- 2014-08-12 RU RU2016101960A patent/RU2016101960A/ru not_active Application Discontinuation
- 2014-08-12 AU AU2014306781A patent/AU2014306781A1/en not_active Abandoned
-
2016
- 2016-07-14 US US15/210,306 patent/US20160317546A1/en not_active Abandoned
-
2017
- 2017-09-18 US US15/707,096 patent/US20180008611A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010132695A5 (enExample) | ||
| JP5714512B2 (ja) | 哺乳動物の内耳及び外耳の感染症の治療に有用な耳科用組成物 | |
| TWI460181B (zh) | 用於治療眼部、耳部或鼻部感染之組成物及方法 | |
| PT2269602E (pt) | Composições de antibiótico para o tratamento do ouvido | |
| MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| RU2015132369A (ru) | Комбинированная терапия для лечения нозокомиальной пневмонии | |
| JP2014510064A5 (enExample) | ||
| Kutz Jr et al. | Ciprofloxacin 0.3%+ dexamethasone 0.1% for the treatment for otitis media | |
| HRP20201307T1 (hr) | Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme | |
| JP2015007136A5 (enExample) | ||
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| EP4218769A3 (en) | Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose | |
| JP2017502074A5 (enExample) | ||
| JP2016527322A5 (enExample) | ||
| US20180008611A1 (en) | Method for treating otic infections after tympanostomy tube placement | |
| WO2011094504A4 (en) | Antimicrobial sinus irrigation compositions, methods, and devices | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| JP2014520874A5 (enExample) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| JP2017516828A5 (enExample) | ||
| JP2011500731A5 (enExample) | ||
| JP2019515000A5 (enExample) | ||
| JP2017530142A5 (enExample) | ||
| JP2013542262A5 (enExample) |